We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Transcriptomics in Systemic Vasculitis (CUTIS) (CUTIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03004326
Recruitment Status : Recruiting
First Posted : December 28, 2016
Last Update Posted : January 13, 2023
Sponsor:
Collaborators:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Center for Advancing Translational Sciences (NCATS)
Office of Rare Diseases Research (ORDR)
Information provided by (Responsible Party):
Peter Merkel, University of Pennsylvania

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

Condition or disease
Cryoglobulinemic Vasculitis (CV) Drug-induced Vasculitis Eosinophilic Granulomatosis With Polyangiitis (EGPA) IgA Vasculitis Isolated Cutaneous Vasculitis Granulomatosis With Polyangiitis (GPA) Microscopic Polyangiitis (MPA) Polyarteritis Nodosa (PAN) Urticarial Vasculitis Vasculitis

Detailed Description:

This study employs a multi-center approach to evaluate cutaneous vasculitis across several forms of idiopathic vasculitis. Patients with cutaneous manifestations of vasculitis will be evaluated by teams of primary vasculitis care providers and Dermatologists in order to facilitate optimal selection of patients and sampling of lesions.

A punch skin biopsy at a site of active vasculitis will be the source of material for histopathologic and transcriptomic evaluation. The histopathology of cutaneous vasculitis will be characterized using a standardized approach.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Actual Study Start Date : January 2017
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vasculitis

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Evaluation of clinical data and linked biopsy specimens [ Time Frame: 1 year ]
    Describe cutaneous vasculitis across several different forms of systemic vasculitis using histopathology.


Biospecimen Retention:   Samples With DNA
Blood samples will be collected solely for research purposes. The reason we are performing these laboratory-based research studies is to help us better understand whether abnormalities detected in a subjects skin biopsy can also be detected in their blood.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

About 56 people with vasculitis will take part in this study at approximately 20 medical centers across North America. Patients with CV, DiV, EGPA, IgA vasculitis, GPA, MPA, PAN, isolated cutaneous vasculitis and urticarial vasculitis will potentially be enrolled into this study.

The protocol will be conducted at the major vasculitis centers in the United States and Canada participating in selected VCRC studies. Skin biopsy specimens collected as standard of care for these diseases will be retrieved and used in research.

Criteria

Inclusion Criteria:

  • Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis

  • Have a suspected or confirmed diagnosis of:

    • Cryoglobulinemic vasculitis (CV)
    • Drug-induced vasculitis
    • Eosinophilic granulomatosis with polyangiitis (EGPA)
    • IgA vasculitis
    • Isolated cutaneous vasculitis
    • Granulomatosis with polyangiitis (GPA)
    • Microscopic polyangiitis (MPA)
    • Polyarteritis nodosa (PAN)
    • Urticarial vasculitis
  • Be willing and able to provide written informed consent (or assent for those under

Exclusion Criteria:

  • You are less than five years old
  • Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy
  • You have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet count less than 50,000/mm3, or a hemoglobin less than 7 g/dL
  • You have an uncontrolled disease that could prevent you from completing the study procedures
  • You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study
  • You are pregnant or nursing
  • You are not able to provide informed consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03004326


Contacts
Layout table for location contacts
Contact: Carol McAlear, MA cmcalear@upenn.edu

Locations
Layout table for location information
United States, California
University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Tandy Ramirez       ItandewyRamirez@mednet.ucla.edu   
United States, Massachusetts
Boston University School of Medicine Completed
Boston, Massachusetts, United States, 02118
United States, Minnesota
Mayo Clinic Completed
Rochester, Minnesota, United States, 55905
United States, Ohio
Cleveland Clinic Completed
Cleveland, Ohio, United States, 44195
United States, Oregon
Oregon Health & Science University Completed
Portland, Oregon, United States
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Josh Bryer       jbryer@pennmedicine.upenn.edu   
United States, Utah
University of Utah Completed
Salt Lake City, Utah, United States
Canada, Ontario
University of Toronto Mount Sinai Hospital Recruiting
Toronto, Ontario, Canada, M5G 1X5
Contact: Suneet Khurana       suneet.khurana@sinaihealth.ca   
Sponsors and Collaborators
Peter Merkel
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Center for Advancing Translational Sciences (NCATS)
Office of Rare Diseases Research (ORDR)
Investigators
Layout table for investigator information
Principal Investigator: Robert Micheletti, MD University of Pennsylvania
Principal Investigator: Peter Grayson, MD, MSc The National Institute of Arthritis and Musculoskeletal and Skin Diseases
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Peter Merkel, Chief, Division of Rheumatology Professor of Medicine and Epidemiology, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03004326    
Other Study ID Numbers: VCRC5563
U54AR057319 ( U.S. NIH Grant/Contract )
First Posted: December 28, 2016    Key Record Dates
Last Update Posted: January 13, 2023
Last Verified: January 2023
Keywords provided by Peter Merkel, University of Pennsylvania:
DIV
CSS
EGPA
HSP
 GPA
MPA
PAN
Wegeners
Additional relevant MeSH terms:
Layout table for MeSH terms
Vasculitis
Systemic Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Granulomatosis with Polyangiitis
Microscopic Polyangiitis
Churg-Strauss Syndrome
Polyarteritis Nodosa
Vascular Diseases
Cardiovascular Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Autoimmune Diseases
 Immune System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Granuloma
Lymphoproliferative Disorders
Lymphatic Diseases
Arteritis
Skin Diseases, Vascular
Skin Diseases